Do you want to read an article? Please log in or register.
Effectiveness of CFTR modulator therapy on risk of death for individuals with cystic fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
Pulmonary Fibrosis
Medication adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: Analysis on the French cystic fibrosis population from 2012-2020
Respir Med
Eid E, Payet C, Fernandez V, Belhassen M, Bessou A, Durieu I, Reynaud Q, Viprey M, French Cystic Fibrosis Centers Network, Cinthia R, Françoise T, Marie-Laure D, Bénédicte RT, Stéphanie B, Julie M, Murie L, Sylvie M, Ralph E, Frédéric H, Manuela S, Laurent M, Rébecca H, Catherine L, Camille A, Nathalie WD, Jane L, Philippe R, Jean-Christophe D, Martine RG, Raphaël C, Aurélie T, Anne G, Isabelle DB, Tiphaine B, Sylvie L, Pierre-Régis B, Isabelle S, Véronique H, Harriet C, Katia BK, Chantal B, Eric D, Sophie R, Christophe M, Nathalie A, Caroline P, Benjamin RP, Laurence W, Dominique G, Léa R, Marlène ME, Julie M, Laure C, Baptiste A, Gabsi Asma
doi: 10.1016/j.rmed.2026.108857
RECOMMENDED
Pulmonary Fibrosis
Comparison of Long Term Effects of Treatment of Different CFTR Modulators in People With Cystic Fibrosis
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Pediatr Pulmonol
Famulska P, Więckowska B, Narożna B, Sapiejka E, Osińska M, Musiał A, Szczepankiewicz A, Tąpolska-Jóźwiak K, Wiesner A, Steinert-Dymecki A, Jóźwiak M, Wojsyk-Banaszak I
doi: 10.1002/ppul.71681
Pulmonary Fibrosis
CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial
Nat Commun
Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, Ulmer N, Hillen B, Birkner T, Bartolomaeus TUP, Nitsche O, Jarquín-Díaz VH, Lynch S, Gehring S, Maier L, Poplawska K, Forslund-Startceva SK
doi: 10.1038/s41467-025-64218-z
RECOMMENDED
Pulmonary Fibrosis
Impact of CFTR Modulator Concentrations on Clinical Response in Cystic Fibrosis
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS, CHEC-SC investigators
doi: 10.1183/13993003.01594-2025
RECOMMENDED
Pulmonary FibrosisRespiratory Tract Infection
Real -World impact of previous exposure to CFTR modulators on clinical parameters and chronic sinus disease in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Holtzlander M, Lind M, Eisner M, Gushue C, Palacios S, Kotha K, Imran S, McCoy K, Sheikh S
doi: 10.1016/j.rmed.2025.108274
RECOMMENDED
Pulmonary FibrosisBronchi
Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
★ 3
Recommended by
Dr. med. Martin Frey, Faculty Member
Lancet Respir Med
Sermet-Gaudelus I, Letierce A, Berteloot L, Bonnel AS, Chen Y, Makani P, Kelly-Aubert M, Kanoun F, Penalva L, Bouleghem N, Bihouee T, Bui S, Corvol H, Houdouin V, Mittaine M, Tatopoulos A, Weiss L, Wizla N, Kapel N, Bessou A, Tiddens HAWM, Caudri D, Reix P, Marguet C, MODUL-CF study group
doi: 10.1016/S2213-2600(25)00248-6
Further Publications
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
Lancet Respir Med
Burgel PR, Da Silva J, Girodon E, Durieu I, Reynaud-Gaubert M, Murris-Espin M, Chiron R, Grenet D, Ramel S, Mely L, Hamidfar R, Douvry B, Houdouin V, Audousset C, Macey J, Mittaine M, Weiss L, Cosson L, Danner-Boucher I, Reix P, Baravalle M, Burnet E, Sermet-Gaudelus I, Martin C, Paillasseur JL, French Cystic Fibrosis Reference Network study group
doi: 10.1016/S2213-2600(25)00190-0
Pulmonary Fibrosis
Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study
J Clin Med
Salvatore D, Campagna G, Padoan R, Pepe A, Amato A, Salvatore M
doi: 10.3390/jcm15072699
RECOMMENDED
Pulmonary Fibrosis
Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, Rosenfeld M, Ratjen F
doi: 10.1016/j.jcf.2025.11.016